Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 03
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
IDEXX Laboratories Inc
IDXX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$518.39
0.64
0.12%
Ult. Agg.: Oct 2, 4:12 PM
$518.39
0.64
0.12%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
IDEXX Laboratories Financials
IDEXX Laboratories (IDXX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.
Vandana Singh
PRO
IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est
IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745
Benzinga Newsdesk
PRO
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from
Benzinga Newsdesk
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency
Idexx Laboratories shares edge higher as revenue tops estimates but earnings per share misses; guidance raised.
Vandana Singh
PRO
CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $3.47 per share which beat the analyst consensus estimate of $3.41 by 1.76 percent. This is a 20.91 percent increase over earnings of $2.87 per share from
Benzinga Newsdesk
Earnings Scheduled For May 5, 2026
Benzinga Insights
